vs
Side-by-side financial comparison of Metallus Inc. (MTUS) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Metallus Inc. is the larger business by last-quarter revenue ($308.3M vs $158.6M, roughly 1.9× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 1.8%, a 69.4% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 9.9%).
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
MTUS vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $308.3M | $158.6M |
| Net Profit | $5.4M | $112.9M |
| Gross Margin | 8.1% | — |
| Operating Margin | — | 70.2% |
| Net Margin | 1.8% | 71.2% |
| Revenue YoY | 9.9% | 3661.1% |
| Net Profit YoY | 315.4% | 528.0% |
| EPS (diluted) | $0.13 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $308.3M | — | ||
| Q4 25 | $267.3M | — | ||
| Q3 25 | $305.9M | — | ||
| Q2 25 | $304.6M | — | ||
| Q1 25 | $280.5M | $158.6M | ||
| Q4 24 | $240.5M | $22.6M | ||
| Q3 24 | $227.2M | — | ||
| Q2 24 | $294.7M | — |
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $8.1M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $1.3M | $112.9M | ||
| Q4 24 | $-21.4M | $-10.5M | ||
| Q3 24 | $-5.9M | — | ||
| Q2 24 | $4.6M | — |
| Q1 26 | 8.1% | — | ||
| Q4 25 | 2.2% | — | ||
| Q3 25 | 11.4% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 5.3% | — | ||
| Q2 24 | 8.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | -7.7% | — | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 1.0% | 70.2% | ||
| Q4 24 | -10.1% | -60.4% | ||
| Q3 24 | -3.1% | — | ||
| Q2 24 | 2.1% | — |
| Q1 26 | 1.8% | — | ||
| Q4 25 | -5.3% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 0.5% | 71.2% | ||
| Q4 24 | -8.9% | -46.4% | ||
| Q3 24 | -2.6% | — | ||
| Q2 24 | 1.6% | — |
| Q1 26 | $0.13 | — | ||
| Q4 25 | $-0.34 | — | ||
| Q3 25 | $0.19 | — | ||
| Q2 25 | $0.09 | — | ||
| Q1 25 | $0.03 | $1.90 | ||
| Q4 24 | $-0.46 | $-0.15 | ||
| Q3 24 | $-0.13 | — | ||
| Q2 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.0M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $683.0M | $350.1M |
| Total Assets | $1.1B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $104.0M | — | ||
| Q4 25 | $156.7M | — | ||
| Q3 25 | $191.5M | — | ||
| Q2 25 | $190.8M | — | ||
| Q1 25 | $180.3M | $274.8M | ||
| Q4 24 | $240.7M | $128.0M | ||
| Q3 24 | $254.6M | — | ||
| Q2 24 | $272.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $5.4M | — | ||
| Q3 24 | $13.2M | — | ||
| Q2 24 | $13.2M | — |
| Q1 26 | $683.0M | — | ||
| Q4 25 | $686.0M | — | ||
| Q3 25 | $697.7M | — | ||
| Q2 25 | $690.0M | — | ||
| Q1 25 | $686.1M | $350.1M | ||
| Q4 24 | $690.5M | $229.0M | ||
| Q3 24 | $712.7M | — | ||
| Q2 24 | $736.3M | — |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | $406.9M | ||
| Q4 24 | $1.1B | $271.6M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $22.0M | — | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $-38.9M | $131.8M | ||
| Q4 24 | $13.9M | $-23.2M | ||
| Q3 24 | $-15.3M | — | ||
| Q2 24 | $8.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-37.2M | — | ||
| Q3 25 | $-6.4M | — | ||
| Q2 25 | $17.0M | — | ||
| Q1 25 | $-66.4M | $131.7M | ||
| Q4 24 | $-1.3M | $-23.2M | ||
| Q3 24 | $-32.9M | — | ||
| Q2 24 | $-5.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | -13.9% | — | ||
| Q3 25 | -2.1% | — | ||
| Q2 25 | 5.6% | — | ||
| Q1 25 | -23.7% | 83.0% | ||
| Q4 24 | -0.5% | -102.7% | ||
| Q3 24 | -14.5% | — | ||
| Q2 24 | -2.0% | — |
| Q1 26 | 0.0% | — | ||
| Q4 25 | 13.2% | — | ||
| Q3 25 | 9.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | 9.8% | 0.1% | ||
| Q4 24 | 6.3% | 0.2% | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 4.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.72× | — | ||
| Q2 25 | 9.41× | — | ||
| Q1 25 | -29.92× | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
